All In Biotech

Drug Trial Radar · NCT02932306

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Participants With Acne Vulgaris

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 820 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

820

Actual

Start

Nov 3, 2015

Primary completion

Feb 22, 2017

Study completion Feb 22, 2017

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Oct 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study was to evaluate the efficacy, safety, and tolerability of a once daily topical application of IDP-121 Lotion compared with its vehicle (IDP-121 Vehicle Lotion) in participants with moderate to severe acne vulgaris (acne) (that is, acne having an Evaluator's Global Severity Score \[EGSS\] of 3 \[moderate\] or 4 \[severe\]).

Conditions

  • Acne

Interventions

  • IDP-121 LotionDrug

    IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.

  • IDP-121 Vehicle LotionDrug

    IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12Time frame: Baseline (Day 0), Week 12
  2. Absolute Change From Baseline in Mean Inflammatory Lesion Count to Week 12Time frame: Baseline, Week 12
  3. Percentage of Participants With Treatment Success at Week 12Time frame: Baseline, Week 12

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Valeant Site 36

    Guntersville, Alabama

  • Valeant Site 14

    Phoenix, Arizona

  • Valeant Site 28

    Hot Springs, Arkansas

  • Valeant Site 38

    Fountain Valley, California

  • Valeant Site 34

    Manhattan Beach, California

  • Valeant Site 23

    Oceanside, California

  • Valeant Site 35

    Ranch Cucamonga, California

  • Valeant Site 20

    San Diego, California

  • Valeant Site 32

    Denver, Colorado

  • Valeant Site 10

    Shelton, Connecticut

  • Valeant Site 02

    Boynton Beach, Florida

  • Valeant Site 15

    Coral Gables, Florida

  • Valeant Site 37

    Miami, Florida

  • Valeant Site 39

    Pembroke Pines, Florida

  • Valeant Site 01

    West Palm Beach, Florida

  • Valeant Site 19

    Boise, Idaho

  • Valeant Site 04

    Arlington Heights, Illinois

  • Valeant Site 27

    Carmel, Indiana

  • Valeant 12

    Plainfield, Indiana

  • Valeant Site 09

    Louisville, Kentucky

  • Valeant Site 16

    Louisville, Kentucky

  • Valeant Site 33

    Needham, Massachusetts

  • Valeant Site 11

    Warren, Michigan

  • Valeant Site 08

    Omaha, Nebraska

  • Valeant Site 25

    Omaha, Nebraska

  • Valeant Site 13

    Berlin, New Jersey

  • Valeant Site 03

    Albuquerque, New Mexico

  • Valeant Site 26

    New York, New York

  • Valeant Site 31

    Stony Brook, New York

  • Valeant 05

    Gresham, Oregon

  • Valeant Site 22

    Fort Washington, Pennsylvania

  • Valeant Site 24

    Charleston, South Carolina

  • Valeant Site 06

    Dallas, Texas

  • Valeant Site 30

    Houston, Texas

  • Valeant Site 17

    Pflugerville, Texas

  • Valeant Site 07

    San Antonio, Texas

  • Valeant 18

    Webster, Texas

  • Valeant Site 29

    Salt Lake City, Utah

  • Valeant Site 21

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.